EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bacillus subtilis engineered for topical delivery of an antifungal agent

Veronica A Montgomery iD, Ethan Cain iD, Mark P Styczynski iD, Mark R Prausnitz

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0293664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Veronica A Montgomery und 3 weiteren Autor:innen. Beteiligte Einrichtung: Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech, Georgia Institute of Technology, Atlanta, GA, United St…. Hauptthemen laut MEDLINE: Bacillus subtilis, Antifungal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, American Association of University Women, National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fungal skin infections are a common condition affecting 20–25 percent of the world population. While these conditions are treatable with regular application of an antifungal medication, we sought to develop a more convenient, longer-lasting topical antifungal platform that could increase patient adherence to treatment regimens by using Bacillus subtilis , a naturally antifungal bacteria found on the skin, for drug production and delivery. In this study, we engineered B . subtilis for increased production of the antifungal lipopeptide iturin A by overexpression of the pleiotropic regulator DegQ. The engineered strain had an over 200% increase in iturin A production as detected by HPLC, accompanied by slower growth but the same terminal cell density as determined by absorbance measurements of liquid culture. In an in vitro antifungal assay, we found that despite its higher iturin A production, the engineered strain was less effective at reducing the growth of a plug of the pathogenic fungus Trichophyton mentagrophytes on an agar plate compared to the parent strain. The reduced efficacy of the engineered strain may be explained by its reduced growth rate, which highlights the need to address trade-offs between titers (e.g. measured drug production) and other figures of merit (e.g. growth rate) during metabolic engineering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bacillus subtilisAntifungal AgentsHumansPeptides, CyclicFungiLipopeptides

Substanzen

Antifungal AgentsPeptides, CyclicLipopeptides

Autor:innen und Institutionen

  • Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech, Georgia Institute of Technology, Atlanta, GA, United States of America.
  • School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, United States of America.

ORCID-Profile: Veronica A Montgomery, Ethan Cain, Mark P Styczynski

Förderung

  • NIBIB NIH HHS
  • American Association of University Women
  • National Science Foundation
  • Tau Beta Pi
  • National Institutes of Health

Zitieren

APA

Montgomery, V. A., Cain, E., Styczynski, M. P., & Prausnitz, M. R. (2023). Bacillus subtilis engineered for topical delivery of an antifungal agent. PLOS ONE. https://doi.org/10.1371/journal.pone.0293664

Vancouver

Montgomery VA, Cain E, Styczynski MP, Prausnitz MR. Bacillus subtilis engineered for topical delivery of an antifungal agent. PLOS ONE. 2023. doi:10.1371/journal.pone.0293664

BibTeX
@article{Montgomery2023,
  author = {Montgomery, Veronica A and Cain, Ethan and Styczynski, Mark P and Prausnitz, Mark R},
  title = {Bacillus subtilis engineered for topical delivery of an antifungal agent},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0293664}
}
Kostenlos starten →